Skip to main content

Decibel Therapeutics, Inc. (DBTX)

NASDAQ: DBTX · IEX Real-Time Price · USD
7.54
+0.23 (3.15%)
After-hours:Oct 22, 2021 7:59 PM EDT
7.31
-0.07 (-0.95%)
At close: Oct 22, 4:00 PM
Market Cap182.01M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out24.87M
EPS (ttm)-3.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,726
Open7.65
Previous Close7.38
Day's Range7.25 - 7.68
52-Week Range6.18 - 24.39
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About DBTX

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance...

IndustryBiotechnology
IPO DateFeb 12, 2021
Employees40
Stock ExchangeNASDAQ
Ticker SymbolDBTX
Full Company Profile

Financial Performance

Financial Statements

News

Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...

3 days ago - GlobeNewsWire

Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...

3 weeks ago - GlobeNewsWire

Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag

The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ: DBTX) lead gene therapy product candidate, DB-OTO, for otoferlin-related cong...

1 month ago - Benzinga

Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Oto...

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...

1 month ago - GlobeNewsWire

Decibel Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...

1 month ago - GlobeNewsWire

Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...

2 months ago - GlobeNewsWire

Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

- Bolstered Board of Directors and Scientific Advisory Board with key appointments -

2 months ago - GlobeNewsWire

Losers Outnumber Gainers in Biotech IPOs This Year

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other symbols:EWTXRXRXTAK
4 months ago - GuruFocus

Decibel Therapeutics Expands World-Class Scientific Advisory Board

Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development Adds leaders with expertise in hearing loss and balance disorders, combined with e...

4 months ago - GlobeNewsWire

Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference

BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and impr...

5 months ago - GlobeNewsWire

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update

– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO –

5 months ago - GlobeNewsWire

Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...

6 months ago - GlobeNewsWire

Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds-

6 months ago - GlobeNewsWire

Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies

Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual...

7 months ago - Benzinga

Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Pr...

Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Research in Ot...

7 months ago - GlobeNewsWire

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

8 months ago - Benzinga

Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...

8 months ago - GlobeNewsWire

Decibel Therapeutics Announces Pricing of Initial Public Offering Nasdaq:DBTX

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...

8 months ago - GlobeNewswire

Catalent and Decibel Team Up to Develop Gene Therapy for Congenital Hearing Loss

Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.

8 months ago - PharmTech

Invitae, Decibel Therapeutics Launch Free Testing Program for Congenital Hearing Loss

Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.

8 months ago - GenomeWeb

Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO

Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.

9 months ago - NASDAQ

Decibel Therapeutics IPO Registration Document (S-1)

Decibel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC

Manufacturers News

...Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M.

9 months ago - The Hearing Journal

Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration

BOSTON--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that th...

10 months ago - Business Wire